Panakeia, LLC Partners with Medasense to Distribute First FDA authorized Nociception Monitor in US Government Institutions

Medasense, a pioneer in pain monitoring technology, has announced a strategic agreement with Panakeia, LLC, a Service-Disabled Veteran-Owned Small Business and a leading healthcare solutions provider, to distribute Medasense's PMD-200 device to United States government institutions.

Continue ReadingPanakeia, LLC Partners with Medasense to Distribute First FDA authorized Nociception Monitor in US Government Institutions

Anesthesia & Analgesia: ”Depth of Anesthesia and Nociception Monitoring: Current State and Vision For 2050.”

Understand the upswing in new monitoring strategies in anesthesia and the key role of NOL monitoring: "Depth of Anesthesia and Nociception Monitoring: Current State and Vision For 2050" (Anesthesia & Analgesia Feb. 2024)

Continue ReadingAnesthesia & Analgesia: ”Depth of Anesthesia and Nociception Monitoring: Current State and Vision For 2050.”

FDA authorizes marketing of Medasense’s NOL (nociception level index) technology through a De Novo grant

Agency clearance paves way for commercialization in the United States of first and only authorized device to measure pain in anesthetized patients undergoing surgery

Continue ReadingFDA authorizes marketing of Medasense’s NOL (nociception level index) technology through a De Novo grant